SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-071549
Filing Date
2020-03-12
Accepted
2020-03-12 16:06:10
Documents
14
Period of Report
2020-03-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d859200d8k.htm   iXBRL 8-K 26131
2 EX-99.1 d859200dex991.htm EX-99.1 56873
6 GRAPHIC g859200img001.jpg GRAPHIC 11603
  Complete submission text file 0001193125-20-071549.txt   231017

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cbay-20200312.xsd EX-101.SCH 3068
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20200312_lab.xml EX-101.LAB 18140
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20200312_pre.xml EX-101.PRE 11407
8 EXTRACTED XBRL INSTANCE DOCUMENT d859200d8k_htm.xml XML 3359
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36500 | Film No.: 20708782
SIC: 2834 Pharmaceutical Preparations